Activation of Phospholipase C-gamma by Phosphatidylinositol 3,4,5-Trisphosphate*

Yun Soo BaeDagger , Lloyd G. Cantley§, Ching-Shih Chen, Seung-Ryul KimDagger par , Ki-Sun KwonDagger , and Sue Goo RheeDagger **

From the Dagger  Laboratory of Cell Signaling, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, the § Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02115, and the  Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40506

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Signal transduction across cell membranes often involves the activation of both phosphatidylinositol (PI)-specific phospholipase C (PLC) and phosphoinositide 3-kinase (PI 3-kinase). Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), a substrate for both enzymes, is converted to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) by the action of PI 3-kinase. Here, we show that PI(3,4,5)P3 activates purified PLC-gamma isozymes by interacting with their Src homology 2 domains. Furthermore, the expression of an activated catalytic subunit of PI 3-kinase in COS-7 cells resulted in an increase in inositol phosphate formation, whereas platelet-derived growth factor-induced PLC activation in NIH 3T3 cells was markedly inhibited by the specific PI 3-kinase inhibitor LY294002. These results suggest that receptors coupled to PI 3-kinase may activate PLC-gamma isozymes indirectly, in the absence of PLC-gamma tyrosine phosphorylation, through the generation of PI(3,4,5)P3.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Activation of both PLC1 and PI 3-kinase often occurs in response to stimulation of cells by a variety of agonists. PLC catalyzes the hydrolysis of PI(4,5)P2 to generate the second messengers inositol 1,4,5-trisphosphate (I(1,4,5)P3) and diacylglycerol (1-3). PI 3-kinase phosphorylates the D-3 position of PI(4,5)P2 to produce PI(3,4,5)P3, which is then sequentially dephosphorylated to PI(3,4)P2 and phosphatidylinositol 3-phosphate (4-7). The activation of each of these two enzymes has been implicated in such diverse cellular processes as mitogenesis, chemotaxis, secretion, and cytoskeletal assembly (4-7).

The phosphoinositides PI(3,4)P2 and PI(3,4,5)P3 are not substrates of any known PLC (8) and are normally absent from resting cells; however, they appear within seconds to minutes of stimulation of cells with various growth factors or other cellular activators. In contrast, the concentration of phosphatidylinositol 3-phosphate does not change substantially in response to cell stimulation (4-7). It has thus been suggested that PI(3,4)P2 and PI(3,4,5)P3 might function as intracellular messengers (4-7). With regard to potential targets of these D-3-phosphorylated lipids, they have been shown to activate Ca2+-independent isoforms of protein kinase C (9, 10) as well as to bind the pleckstrin homology (PH) domain of the protein serine-threonine kinase Akt, thereby activating its kinase activity (11-13), and to the SH2 domains of the 85-kDa (p85) subunit of PI 3-kinase, thereby preventing its binding to tyrosine-phosphorylated proteins (14).

The 10 mammalian PLC isozymes identified to date are single polypeptides and can be divided into three types: PLC-beta , PLC-gamma , and PLC-delta (1). All contain a PH domain in their NH2-terminal region. The gamma  type isozymes differ from the other two types in that they contain two SH2 domains, one SH3 domain, and an additional PH domain that is split by the SH domains; these domains are arranged in the order PH(N)-SH2-SH2-SH3-PH(C), where N and C in parentheses denote NH2- and COOH-terminal locations, respectively. Upon stimulation of cells with growth factors like platelet-derived growth factor (PDGF) and epidermal growth factor, the SH2 domain of PLC-gamma binds to the autophosphorylated tyrosine residues of growth factor receptors, leading to tyrosine phosphorylation and activation of PLC-gamma (1). PLC isozymes can also be activated at least in vitro by the presence of phosphatidic acid (15) or arachidonic acid (16). Therefore, activation of PLC-gamma isozymes may occur secondarily to receptor-mediated activation of phospholipase D and cytosolic phospholipase A2, which results in the production of phosphatidic acid and arachidonic acid, respectively. We now report that another lipid-derived messenger, PI(3,4,5)P3, activates PLC-gamma isozymes specifically by interacting with their SH2 domains.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Materials-- PLC isozymes were purified from HeLa cells that had been transfected with recombinant vaccinia virus containing the entire coding sequence of the respective enzyme (17). Dipalmitoyl-PI(3,4)P2 and dipalmitoyl-PI(3,4,5)P3 were synthesized as described (18). An expression vector (pCMVp110-CAAX) that encodes a fusion protein consisting of Myc epitope and p110-CAAX was kindly provided by J. Downward (Imperial Cancer Fund, London, United Kingdom).

PLC Assay-- The activities of PLC-beta 1, PLC-gamma 1, PLC-gamma 2, and PLC-delta 1 were measured with a mixed micellar substrate containing [3H]PI(4,5)P2, phosphatidylethanolamine, and phosphatidylserine in a molar ratio of 1:3:3 together with various amounts of synthetic dipalmitoyl-PI(3,4,5)P3 or dipalmitoyl-PI(3,4)P2 in 0.1% deoxycholate. The final assay mixture (100 µl) contained 10 µM [3H]PI(4,5)P2 (26,000 cpm), 50 mM Hepes-NaOH (pH 7.0),10 mM NaCl, 120 mM KCl, 2 mM EGTA, 0.05% deoxycholate, bovine serum albumin (5 µg/ml), 1 µM free Ca2+, and the indicated concentrations of PI(3,4,5)P3 or PI(3,4)P2. After incubation for 10 min at 30 °C, the reaction was terminated by addition of 200 µl of 10% (w/v) trichloroacetic acid and 100 µl of 10% (w/v) bovine serum albumin, followed by centrifugation. The amount of radioactivity in the resulting supernatant, corresponding to [3H]I(1,4,5)P3, was measured by liquid scintillation spectroscopy. The amount of PLC isozymes (4-7 ng) was adjusted to give similar basal activity.

Preparation of GST Fusion Proteins-- For each fusion protein (denoted PH(N)-SH2-SH2-SH3-PH(C), SH2-SH2-SH3, SH2-SH2, N-SH2, C-SH2, PH(NC), and SH3), the corresponding polymerase chain reaction product, flanked by BamHI and EcoRI linkers, was inserted into the BamHI and EcoRI sites of the glutathione S-transferase (GST) expression vector pGEX-2TK (Pharmacia Biotech Inc.). Amino acid sequences of PH(N)-SH2-SH2-SH3-PH(C), SH2-SH2-SH3, SH2-SH2, N-SH2, C-SH2, and SH3 correspond to residues 483-936, 533-851, 550-745, 550-657, 668-745, and 758-851 of PLC-gamma 1, respectively. Polymerase chain reaction products corresponding to residues 482-523 (PH(N)) and 865-936 (PH(C)) of PLC-gamma 1 were fused with a glycine codon insertion to yield the combined PH(NC) construct. The 5' and 3' primers for PH(N) contained BamHI and SmaI sites, respectively; thus, the PH(NC) construct contained sequential BamHI, SmaI, and EcoRI sites. Escherichia coli cells were transformed with the various expression vectors and cultured at 30 °C. Expression of the GST fusion proteins was induced with 0.1 mM isopropyl-1-thio-beta -D-galactopyranoside, and the cells were subsequently collected by centrifugation at 2000 × g for 15 min, sonicated in phosphate-buffered saline, and centrifuged at 5000 × g for 15 min. The resulting supernatant was mixed and incubated at room temperature for 30 min with 2 ml of a 50% (v/v) slurry of glutathione-Sepharose 4B (Pharmacia) that had been equilibrated with phosphate-buffered saline. After centrifugation of the mixture at 5000 × g for 15 min, the supernatant was removed and the pellet washed with 10 bed volumes of phosphate-buffered saline. Bound proteins were cleaved from GST by incubation of the beads with thrombin (10 µg/ml) at room temperature for 6 h. The eluted proteins were further purified by high performance liquid chromatography on a Mono Q column and quantitated spectrophotometrically with extinction coefficients at 280 nm calculated on the basis of their amino acid composition.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

We investigated the effects of PI(3,4)P2 and PI(3,4,5)P3 on the activities of PLC isozymes by measuring the hydrolysis of PI(4,5)P2 with mixed micellar substrates containing phosphatidylethanolamine, phosphatidylserine, [3H]PI(4,5)P2, and various amounts of synthetic D-3-phosphorylated lipids. PI(3,4,5)P3 increased the activities of PLC-gamma 1 and PLC-gamma 2 but had no effect on PLC-beta 1 or PLC-delta 1 (Fig. 1A). The dependence of the activities of PLC-gamma 1 and PLC-gamma 2 on PI(3,4,5)P3 concentration was sigmoidal, with maximal activation (approximately 8-fold) apparent at 100 µM lipid. In contrast, PI(3,4)P2 had no effect on the activities of any of the PLC isozymes examined (Fig. 1B).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of PI(3,4,5)P3 and PI(3,4)P2 on the hydrolysis of PI(4,5)P2 by various PLC isozymes. The activities of PLC-beta 1, PLC-gamma 1, PLC-gamma 2, and PLC-delta 1 were measured with a mixed micellar substrate containing various amounts of PI(3,4,5)P3 (A) and PI(3,4)P2 (B) as described under "Experimental Procedures." Data are means of duplicate measurements from a single experiment and are representative of three similar experiments.

We prepared various recombinant proteins containing different domains of PLC-gamma 1 (Fig. 2, A and B) and measured their effects on the activity of full-length PLC-gamma 1 in the presence of 100 µM PI(3,4,5)P3. All SH2 domain-containing proteins inhibited the PI(3,4,5)P3-stimulated activity of PLC-gamma 1 in a concentration-dependent manner, whereas proteins corresponding to the SH3 and PH(NC) (fusion of PH(N) and PH(C)) domains had no effect (Fig. 2C). The inhibition by SH2 proteins was apparent only in the presence of PI(3,4,5)P3, the basal activity of PLC-gamma 1 being unaffected (Fig. 2D). These results suggest that PI(3,4,5)P3 activates PLC-gamma isozymes by binding to their SH2 domains. Furthermore, the three proteins PH(N)-SH2-SH2-SH3-PH(C), SH2-SH2-SH3, and SH2-SH2, all of which contain two SH2 domains, inhibited PI(3,4,5)P3-dependent PLC-gamma 1 activity to a greater extent than did the NH2-terminal SH2 (N-SH2) or COOH-terminal SH2 (C-SH2) domains alone. This result, together with the sigmoidal response of PLC-gamma isozyme activities to PI(3,4,5)P3, indicates that the two SH2 domains bind PI(3,4,5)P3 with positive cooperativity or that the two PI(3,4,5)P3-bound domains mediate enzyme activation synergistically. The ability of PI(3,4,5)P3 but not PI(3,4)P2 to activate PLC-gamma 1 via its SH2 domains is consistent with the previous observation that p85, Src, and Abl SH2 domains show higher affinity for PI(3,4,5)P3 than for PI(3,4)P2 or PI(4,5)P2 (14). PLC-gamma isozymes contain an additional PH domain near their NH2 terminus. Recent results by Falasca et al. (19) suggest that PI(3,4,5)P3 may also bind to the PH domain (19).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of various recombinant PLC-gamma 1 domain-containing proteins on PI(3,4,5)P3-dependent PLC-gamma 1 activity. A, schematic representation of the recombinant PLC-gamma 1 constructs. The top scheme shows the SH2, SH3, and split PH [PH(N) and PH(C)] domains of PLC-gamma 1 flanked by the X and Y catalytic domains. The recombinant constructs shown below were expressed as GST fusion proteins in E. coli, purified, and cleaved from GST. The PH(NC) construct comprises the fused PH(N) and PH(C) domains with an inserted glycine residue between them. B, analysis of the purity of the recombinant PLC-gamma 1 protein preparations. The purified proteins were analyzed by SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining. Lane 1, PH(N)-SH2-SH2-SH3-PH(C); lane 2, SH2-SH2-SH3; lane 3, SH2-SH2, lane 4, NH2-terminal SH2 (N-SH2); lane 5, COOH-terminal SH2 (C-SH2); lane 6, PH(NC); lane 7, SH3. The positions of molecular size standards (in kilodaltons) are shown on the left. C, effects of recombinant proteins on the activity of full-length PLC-gamma 1 in the presence of PI(3,4,5)P3. The hydrolysis of [3H]PI(4,5)P2 by 1.1 nM PLC-gamma 1 was measured in the presence of the indicated concentrations of the various recombinant proteins and 100 µM PI(3,4,5)P3 as described under "Experimental Procedures." D, effects of recombinant proteins on basal PLC-gamma 1 activity. The activity of PLC-gamma 1 was assayed as in C but in the absence of PI(3,4,5)P3. Data in C and D are means of duplicate measurements from a single experiment and are representative of three similar experiments.

The concentration of PI(3,4,5)P3 required for activation of PLC-gamma isozymes in vitro is relatively high. However, it has been suggested that the intracellular concentration of PI(3,4,5)P3 can achieve values of up to 200 µM in neutrophils stimulated with formylmethionyl-leucyl-phenylalanine (fMLP) (20). Specific generation of PI(3,4,5)P3 at sites of PLC-gamma localization might be one means of ensuring effective activation of PLC-gamma isozymes. The sigmoidal response to PI(3,4,5)P3 also suggests that PLC-gamma activation would be minimal until the lipid concentration exceeds a certain threshold.

To determine whether activation of PLC by PI(3,4,5)P3 could be detected in intact cells, we transiently expressed in COS-7 cells the 110-kDa subunit (p110) of PI 3-kinase with c-Myc epitope and farnesylation signal (CAAX) sequences located at the NH2 and COOH termini, respectively (21), and measured the release of inositol phosphates resulting from the hydrolysis of PI(4,5)P2. Expression of the Myc-tagged p110-CAAX protein was detected by immunoblot analysis with antibodies specific to the Myc sequence (Fig. 3A). The farnesylation signal sequence causes the constitutive activation of p110 by targeting it to the cell membrane. As expected from the fact that most mammalian cells contain a relatively high concentration (>20 µM) of inositol phosphates even before stimulation (22), a substantial amount of 3H-labeled inositol phosphates was detected in COS-7 cells labeled with [3H]inositol to equilibrium (Fig. 3). Expression of Myc-p110-CAAX induced a 45% increase in the amount of inositol phosphates, and this effect was blocked by pretreatment of cells with LY294002, a specific inhibitor of PI 3-kinase (23). LY294002 had no effect on the amount of inositol phosphates in cells not expressing Myc-p110-CAAX. These results suggest that PI(3,4,5)P3 generated by the activated p110 subunit was able to activate PLC. The increase in PLC activity was smaller than that in cells stimulated with PLC-activating agonists, probably because in the local area where PLC-gamma was activated by PI(3,4,5)P3, PI(4,5)P2 (a common substrate for PLC and PI 3-kinase) had been depleted by Myc-p110-CAAX. It has been shown previously that availability of PI(4,5)P2 is a limiting factor for PLC activity (24).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of the expression of an activated p110 subunit of PI 3-kinase on inositol phosphate formation in COS-7 cells. COS-7 cells were plated at a density of 3 × 105 cells/well in six-well plates and allowed to recover for 24 h. The cells were then incubated for 6 h with 1.3 µg of empty (pCMV) or Myc-p110-CAAX-encoding (pCMVp110-CAAX) plasmid and 6.7 µl of LipofectAMINE in 1 ml of Opti-MEM medium (Life Technologies, Inc.), after which 1 ml of Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum was added to each well and the cells were incubated for an additional 24 h. The medium was then aspirated, and cells were incubated for 16 h in myo-inositol-free DMEM supplemented with [3H]myo-inositol (1 µCi/ml, 25 mCi/mmol) (DuPont Biotechnology Systems). The cells were then incubated in the absence or presence of 10 µM LY294002 for 45 min, followed by additional incubation in DMEM supplemented with 20 mM LiCl for 60 min. The incubation was terminated by adding perchloric acid to a final concentration of 5% (w/v). Cells were scraped into Eppendorf tubes and subjected to centrifugation. A, the resulting pellets were subjected to immunoblot analysis with antibodies to Myc (Santa Cruz Biotechnology). Arrow indicates Myc-p110-CAAX protein. B, the amount of total [3H]inositol phosphates in the cell supernatants was measured as described (34). Data are expressed as a percentage of the values for pCMV-transfected cells not treated with LY294002 and are means ± S.E. from three independent experiments.

Further evidence that PI(3,4,5)P3 activates PI(4,5)P2 hydrolysis in intact cells is provided by previous studies with wortmannin, a potent (median inhibitory concentration (IC50), 3 nM), irreversible inhibitor of PI 3-kinase (23). Wortmannin inhibits I(1,4,5)P3 formation and Ca2+ mobilization in bovine adrenal glomerulosa cells stimulated by angiotensin II (25), rat basophilic leukemia (RBL-2H3) cells stimulated by cross-linking of high affinity immunoglobulin E (IgE) receptors (26), and human neutrophils stimulated by fMLP (27). At the time of the studies with neutrophils and adrenal glomerulosa cells, wortmannin was known to inhibit myosin light chain kinase (MLCK), but its effect on PI 3-kinase was not known. The inhibition of I(1,4,5)P3 and Ca2+ responses by 20 nM wortmannin in adrenal glomerulosa cells was thus speculated to result from inhibition of MLCK. However, it is now known that the concentration of wortmannin required for inhibition of MLCK is 100 times that required for inhibition of PI 3-kinase (23), so that MLCK was likely not inhibited by 20 nM wortmannin. Our data indicate that they are likely attributable to prevention of PI(3,4,5)P3-induced activation of PLC-gamma . PLC-gamma 1 is a widely expressed and abundant enzyme, whereas PLC-gamma 2 is abundant in cells of hematopoietic origin.

Recently, type III PI 4-kinase was shown to be inhibited by wortmannin (IC50, 50 nM) (23). Because PI 4-kinase is required for PI(4,5)P2 synthesis, it is possible that the reduced activity of PLC observed in wortmannin-treated cells was attributable to the diminished supply of substrate. Thus, we studied the effect of the more specific inhibitor LY294002 (IC50: 2 and 100 µM for PI 3-kinase and type III PI 4-kinase, respectively; Ref. 23) on PI(4,5)P2 hydrolysis induced by PDGF in NIH 3T3 cells. Whereas PDGF induced an 8-fold increase in PLC activity in control cells, pretreatment of cells with 10 µM LY294002 reduced this response by 40% (Fig. 4A). The presence of the inhibitor affected neither the basal amount of inositol phosphates (Fig. 4A) nor the tyrosine phosphorylation of PLC-gamma 1 and PDGF receptor (Fig. 4B). In a similar experiment with COS-7 cells, epidermal growth factor induced a 3-fold increase in PLC activity and pretreatment of cells with 10 µM LY294002 reduced the response by 34% (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of LY294002 on the PDGF-induced production of inositol phosphates in NIH 3T3 cells. A, NIH 3T3 cells were labeled with [3H]myo-inositol as described in Fig. 3, and then incubated first in the absence or presence of 10 µM LY294002 for 45 min and then with or without PDGF (50 ng/ml) for 10 min in the presence of 20 mM LiCl. Total [3H]inositol phosphates were then measured as described in Fig. 3. Data are expressed as a percentage of the value for cells not exposed to LY294002 or PDGF and are means ± S.E. from three independent experiments. B, NIH 3T3 cells were incubated in the absence or presence of 10 µM LY294002 for 45 min and then with or without PDGF (50 ng/ml) for 10 min. Cell lysates were subjected to immunoblot analysis with antibodies to PLC-gamma 1 (alpha PLC-gamma 1, left panel) or with antibodies to phosphotyrosine (alpha PY, right panel). The positions of PLC-gamma 1 as well as tyrosine-phosphorylated PLC-gamma 1 and PDGF receptor (PDGFR) are indicated.

Characterized mechanisms for the activation of PLC isozymes include the phosphorylation of PLC-gamma isoforms by protein-tyrosine kinases (PTKs) and the interaction of PLC-beta isozymes with G proteins (1-3). Tyrosine phosphorylation of PLC-gamma requires SH2 domain-mediated association with a tyrosine-phosphorylated PTK. Because PI(3,4,5)P3 competes with tyrosine-phosphorylated proteins for binding to SH2 domains, an increase in PI(3,4,5)P3 concentration might attenuate PTK-dependent activation of PLC-gamma . PI 3-kinase exists in two types: one that is activated by PTKs and one activated by G proteins (4-7). The PTK-activated PI 3-kinase is a heterodimer of an 85-kDa regulatory subunit (p85alpha ,beta ) and a 110-kDa catalytic subunit (p110alpha ,beta ), whereas the G protein-activated PI 3-kinase consists of a single polypeptide of 110 kDa (p110gamma ) (28-30).

More than 60 different receptors are known to stimulate PLC (1-3). Although only 30 receptors are currently known to stimulate PI 3-kinase (4-7), most of these also activate PLC. Therefore, the amount of I(1,4,5)P3 generated in a variety of cells in response to an agonist may reflect the sum of that produced as a result of direct activation of PLC and that produced by indirect activation of PLC-gamma through the PI 3-kinase pathway. Given that LY294002, at a concentration sufficient for inhibition of PI 3-kinase but not for inhibition of PI 4-kinase, inhibits 40% of PDGF-dependent PLC activity, the ratio of direct to indirect activation appears to be 3 to 2 in NIH 3T3 cells stimulated with PDGF. The indirect activation of PLC-gamma is likely not limited to PTK receptors such as the PDGF receptor and PTK-coupled receptors such as the IgE receptor. The fact that wortmannin inhibits PLC activation induced by G protein-coupled receptors such as those for angiotensin II and fMLP suggests that PLC-gamma might be activated indirectly in response to the occupancy of such receptors. However, the activation of PI 3-kinase appears not always to result in activation of PLC-gamma , because there is no evidence that insulin or colony-stimulating factor-1, both of which activate PI 3-kinase, elicits the production of I(1,4,5)P3 (31, 32). One possible explanation is that PLC-gamma isozymes may not be located at the sites where PI(3,4,5)P3 is generated in the cells activated with colony-stimulating factor or insulin.

Finally, our results may explain how engagement of the Fcepsilon RIIB inhibitory receptor in mast cells reduces the IgE-induced increase in intracellular Ca2+ concentration (33). Fcepsilon RIIB binds SHIP, a phosphatase that dephosphorylates the D-5 position of PI(3,4,5)P3 or I(1, 3,4,5)P4. A decrease in the concentration of PI(3,4,5)P3 could reduce I(1,4,5)P3 production by PLC-gamma isozymes and thereby reduce long term release of intracellular Ca2+ and ultimately Ca2+ influx.

    ACKNOWLEDGEMENTS

We thank J. Downward and A. Toker for the Myc-tagged p110-CAAX expression vector and Lewis Cantley for valuable discussions and comments on the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants DK48871 (to L. G. C.) and GM53448 (to C.-S. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

par Present address: Dept. of Biochemistry, Chungbuk National University Medical School, Chongju 361-763, Korea.

** To whom correspondence should be addressed: National Institutes of Health, Bldg. 3, Rm. 122, 3 Center Dr., MSC 0320, Bethesda, MD 20892-0320. Tel.: 301-496-9646; Fax: 301-480-0357.

1 The abbreviations used are: PLC, phosphatidylinositol-specific phospholipase C; PI 3-kinase, phosphoinositide 3-kinase; PI(4,5)P2, phosphatidylinositol 4,5-bisphosphate; PI(3,4)P2, phosphatidylinositol 3,4-bisphosphate; PI(3,4,5)P3, phosphatidylinositol 3,4,5-trisphosphate; I(1,4,5)P3, inositol 1,4,5-trisphosphate; SH2, Src homology 2; PH, pleckstrin homology; p85, the 85-kDa regulatory subunit of PI 3-kinase; p110, the 110-kDa catalytic subunit of PI 3-kinase; GST, glutathione S-transferase; fMLP, formylmethionyl-leucyl-phenylalanine; PDGF, platelet-derived growth factor; MLCK, myosin light chain kinase; PTK, protein-tyrosine kinase; DMEM, Dulbecco's modified Eagle's medium.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Rhee, S. G., and Bae, Y. S. (1997) J. Biol. Chem. 272, 15045-15048[Free Full Text]
  2. Cockcroft, S., and Thomas, G. M. H. (1992) Biochem. J. 288, 1-14[Medline] [Order article via Infotrieve]
  3. Berridge, M. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve]
  4. Cantley, L., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, R., Kapeller, R., and Solotoff, S. (1991) Cell 64, 281-302[Medline] [Order article via Infotrieve]
  5. Fry, M., and Waterfield, M. D. (1993) Phil. Trans. R. Soc. London Series B 340, 337-344
  6. Stephens, L., Jackson, T., and Hawkins, P. (1993) Biochim. Biophys. Acta 1179, 27-75[Medline] [Order article via Infotrieve]
  7. Kapeller, R., and Cantley, L. (1994) BioEssays 16, 565-576[Medline] [Order article via Infotrieve]
  8. Serunian, L. A., Haber, M. T., Fukui, T., Kim, J. W., Rhee, S. G., Lowenstein, J. M., Cantley, L. C. (1989) J. Biol. Chem. 264, 17809-17915[Abstract/Free Full Text]
  9. Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16[Abstract/Free Full Text]
  10. Toker, A., Meyer, M., Reddy, K. K., Falch, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367[Abstract/Free Full Text]
  11. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., Tsichlis, P. N. (1995) Cell 81, 727-736[Medline] [Order article via Infotrieve]
  12. Franke, T. F., Kaplan, D. R, Cantley, L. C., Toker, A. (1997) Science 275, 665-668[Abstract/Free Full Text]
  13. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., Hawkins, P. T. (1997) Science 277, 567-570[Abstract/Free Full Text]
  14. Rameh, L., Chen, C.-S., and Cantley, L. C. (1995) Cell 83, 821-830[Medline] [Order article via Infotrieve]
  15. Jones, G. A., and Carpenter, G. (1993) J. Biol. Chem. 268, 20845-20850[Abstract/Free Full Text]
  16. Hwang, S. C., Jhon, D.-Y., Bae, Y. S., Kim, J. H., Rhee, S. G. (1996) J. Biol. Chem. 271, 18342-18349[Abstract/Free Full Text]
  17. Park, D., Jhon, D.-Y., Kriz, R., Knopf, J., and Rhee, S. G. (1992) J. Biol. Chem. 267, 16048-16055[Abstract/Free Full Text]
  18. Wang, D.-S., and Chen, C.-S. (1996) J. Org. Chem. 61, 5905-5906[CrossRef]
  19. Falasca, M., Logan, S. K., Lehto, V. P., Baccante, G., Lemmon, M. A., and Schlessinger, J. (1998) EMBO J., in press
  20. Stephens, L. R., Hughes, K. T., and Irvine, R. F. (1991) Nature 351, 33-39[CrossRef][Medline] [Order article via Infotrieve]
  21. Khwaja, A., Rodriguez-Viciana, P., Wennström, S., Warne, P. H., Downward, J. (1997) EMBO J. 16, 2783-2793[Abstract/Free Full Text]
  22. Szwergold, B. S., Graham, R. A., and Brown, T. R. (1987) Biochem. Biophys. Res. Commun. 149, 874-881[Medline] [Order article via Infotrieve]
  23. Downing, G. J., Kim, S., Nakanishi, S., Catt, K. J., Balla, T. (1996) Biochemistry 19, 3587[CrossRef]
  24. Cunningham, E., Tan, s. K., Swigart, P., Hsuan, J., Bankaitis, V., and Cockcroft, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6589[Abstract/Free Full Text]
  25. Nakanishi, S., Catt, K. J., and Balla, T. (1994) J. Biol. Chem. 269, 6528-6535[Abstract/Free Full Text]
  26. Baker, S., Caldwell, K. K., Hall, A., Martinez, M., Pfeiffer, J. R., Oliver, J. M., Wilson, B. S. (1995) Mol. Biol. Cell 6, 1145-1158[Abstract]
  27. Bonser, R. W., Thompson, N. T., Randall, R. W., Tateson, J. E., Spacey, G. D., Hodson, H. F., Garland, L. G. (1991) Br. J. Pharmacol. 103, 1237-1241[Abstract]
  28. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., and Dhand, R. (1995) Science 269, 690-693[Medline] [Order article via Infotrieve]
  29. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., Hawkin, P. T. (1994) Cell 77, 83-93[Medline] [Order article via Infotrieve]
  30. Thomason, P., James, S. R., Casey, P. J., Downes, C. P. (1994) J. Biol. Chem. 269, 16525-16528[Abstract/Free Full Text]
  31. Whetton, A. D., Monk, P. N., Consalvey, S. D., Downes, C. P. (1986) EMBO J. 5, 3281-3286[Abstract]
  32. Nishibe, S., Wahl, M. I., Wedegaertner, P. B., Kim, J. W., Rhee, S. G., Carpenter, G. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 424-428[Abstract]
  33. Ono, M., Bolland, S., Tempst, P., and Ravetch, J. V. (1996) Nature 383, 263-266[CrossRef][Medline] [Order article via Infotrieve]
  34. Downes, C. P., Hawkins, P. T., and Irvine, R. F. (1986) Biochem. J. 238, 501-506[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.